Feature Candel enhancing cancer patient survival and quality of life with breakthrough viral immunotherapies Candel Therapeutics (NASDAQ:CADL) is developing off-the-shelf multimodal viral immunotherapies for individualized systemic anti-tumor immune response, specific to the patient’s difficult-to-treat cancer, improving... June 25, 2024